Human immunodeficiency virus type 1 Vpr modulates cellular expression of UNG2 via a negative transcriptional effect.
It was recently reported that human immunodeficiency virus type 1 (HIV-1) Vpr induced the proteasomal degradation of the nuclear UNG2 enzyme for efficient virus replication. We confirm here that HIV-1 infection and Vpr expression reduce the level of endogenous UNG2, but this effect is not reverted by treatment with the proteasome inhibitor MG132. Moreover, this reduction is not mediated by Vpr binding to UNG2 and is independent of the Vpr-induced G(2) arrest. Finally, we show that Vpr influences the UNG2 promoter without affecting UNG1 gene expression. These data indicate that the Vpr-induced decrease of UNG2 level is mainly related to a transcriptional effect.
Langevin
Christelle
C
Institut Cochin, CNRS UMR 8104, Université Paris Descartes, Paris, France.
Maidou-Peindara
Priscilla
P
Aas
Per Arne
PA
Jacquot
Guillaume
G
Otterlei
Marit
M
Slupphaug
Geir
G
Benichou
Serge
S
D002453:Cell Cycle; D002467:Cell Nucleus / Q000378:metabolism; D045647:DNA Glycosylases / Q000096:biosynthesis*; D016195:G2 Phase; D015967:Gene Expression Regulation, Viral; D015497:HIV-1 / Q000235:genetics; D006367:HeLa Cells; D006801:Humans; D007976:Leupeptins / Q000494:pharmacology; D008856:Microscopy, Fluorescence / Q000379:methods; D011401:Promoter Regions, Genetic; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D061988:Proteasome Inhibitors; D014158:Transcription, Genetic; D014779:Virus Replication; D054325:vpr Gene Products, Human Immunodeficiency Virus / Q000378:metabolism*
D007976:Leupeptins; D061988:Proteasome Inhibitors; D054325:vpr Gene Products, Human Immunodeficiency Virus; C492570:CCNO protein, human; D045647:DNA Glycosylases; D046988:Proteasome Endopeptidase Complex; C072553:benzyloxycarbonylleucyl-leucyl-leucine aldehyde